Peak HumanDatabase
    All Research
    PAPER AASLD-Expert Consensus

    AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (2023)

    2023 AASLD guidance recommends FIB-4 as the first-line non-invasive test to risk-stratify MASLD/NAFLD; FIB-4 <1.3 rules out advanced fibrosis and >=2.67 flags higher risk needing secondary testing.

    Evidence

    9/10

    Strong Evidence

    Sample

    —

    subjects

    Duration

    —

    study period

    Journal

    Hepatology

    02

    Key Findings

    1. 01

      FIB-4 recommended as first-line non-invasive fibrosis test in MASLD

    2. 02

      <1.3 rule-out; >=2.67 higher risk; age >=65 uses ~2.0 rule-out

    03

    Structured Methods

    Study Design
    Expert Consensus
    Sample Size
    Not reported
    Study Duration
    Not reported
    Methodology
    Not reported
    Limitations
    Not reported
    04

    Citations & References

    Cite this paper

    Unknown authors (n.d.). AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (2023). Hepatology.

    Source

    Publisher

    Journal

    Hepatology

    05

    Indexing

    Topics

    liver fibrosisMASLDguideline

    Biomarkers

    FIB-4 Index
    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation
    See your Peak Human Score How it works